India Unveils Genome Sequencing Data of 10,000 Individuals: A Milestone in Biotechnology Research

Ambry Genetics Advances BRCA2 Variant Classification with CRISPR-Based Study Published in *Nature*

Geneoscopy Secures $105M Series C Funding to Advance Colorectal Cancer Screening

Vertex and Orna Partner to Develop In Vivo Gene Therapies for Blood Disorders

FDA Grants Priority Review to Dizal’s Sunvozertinib for EGFR Exon20ins NSCLC

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

Pillar Biosciences Partners with MSK to Enhance Precision Oncology with OncoKB™ Integration

CytoMed and SunAct Partner to Advance Allogeneic Gamma Delta T Cell Therapy in India

China’s NMPA Approves Astellas’ Zolbetuximab for Advanced Gastric and GEJ Cancer

Renovaro to Acquire Predictive Oncology in All-Stock Deal

Portage Biotech Relaunches Subsidiary as Cyncado Therapeutics to Advance Next-Generation Immuno-Oncology Therapies

ADSCC Pioneers Clinical-Grade iPSCs, Advancing Regenerative Medicine in the Middle East

Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Home
/
update
/
details

MD Anderson and Myriad Genetics Forge Strategic Alliance to Advance MRD Testing in Cancer Care

NextEdge Admin

08 Jan 2025

2 min 26 sec

Myriad Genetics,molecular residual disease,research

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. have announced a five-year strategic alliance to advance the clinical evaluation of Myriad’s molecular residual disease (MRD) assay, Precise MRD. This collaboration leverages Myriad’s expertise in oncology diagnostics and MD Anderson’s leadership in clinical and translational research to assess the test’s validity and utility.

“We look forward to working with MD Anderson to evaluate Precise MRD’s role in cancer care,” said Dale Muzzey, PhD, Chief Scientific Officer at Myriad Genetics. “Our studies will explore how this ultrasensitive test can refine treatment strategies and improve patient outcomes. By detecting tumor-derived DNA at significantly lower levels than first-generation MRD tests, Precise MRD has the potential to enhance therapy-response and recurrence monitoring.”

MD Anderson and Myriad will conduct retrospective and prospective studies across breast, gastrointestinal, genitourinary, and gynecologic cancers to generate evidence supporting national guideline inclusion and provider adoption. MD Anderson investigators will lead patient enrollment, sample collection, data analysis, and manuscript development, while Myriad will provide funding, MRD testing, and scientific research support, including potential milestone and royalty payments.

“This collaboration integrates Myriad’s cutting-edge MRD technology with MD Anderson’s disease-focused expertise,” said Christopher Flowers, M.D., division head of Cancer Medicine at MD Anderson. “We aim to explore MRD’s role in relapse monitoring, risk stratification, and potential intervention strategies.”

The alliance builds on existing collaborations in breast cancer and renal cell carcinoma, further expanding research efforts to enhance cancer care.